UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public. 

The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

Ochre Bio co-founder and CEO, Jack O’Meara, spoke to Medtech Insight about the company’s human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how a fledgling drug company's early work can mirror that seen in diagnostics.